Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerbations of Blepharitis

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerbations of Blepharitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Blepharitis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms DANUBE
  • Sponsors NicOx

Most Recent Events

  • 13 Oct 2020 Primary endpoint has been met, according to a NicOx media release.
  • 08 Apr 2020 According to a NicOx media release, the company has held a Type C meeting with the U.S. Food and Drug Administration (FDA) in which the data from this study was reviewed and the next NCX 4251 trial designs were discussed.
  • 06 Mar 2020 According to a NicOx media release, NCX 4251 Danube Phase 2 results were presented at American Glaucoma Society (February 27 to March 1, 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top